Q-omics provides the consensus-scored ZNF593 profile across patient tissues and cancer cell-line models. ZNF593 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF593 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ZNF593 RNA expression shows 18,492 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ZNF593 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF593 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF593 survival associations across molecular data types. ZNF593 RNA expression shows survival associations in the most cancer types (19), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF593 RNA expression–survival associations across cancer types. High ZNF593 expression shows unfavorable associations in KIRC, ACC, LGG, HNSC and UCS, but favorable associations in COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF593 RNA expression.
This table summarizes ZNF593 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF593. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF593 shows lower tumor expression in KICH and higher tumor expression in COAD, BLCA, STAD, LUAD and HNSC. The COAD box plot shows higher ZNF593 RNA expression in tumor versus normal tissue (log2 FC = +1.429, t-test p < 0.001).
This table shows molecular features associated with ZNF593 in patient tissues and cancer cell lines. In patient samples, ZNF593 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF593 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
